Charles S. Fuchs was named President of Erasca, Inc., effective August 10, 2026. As of November 6, 2026, Erasca, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 10, 2026 to October 16, 2026, naming 1 appointment (Form 8-K, August 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Erasca, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Erasca, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-10 to 2026-10-16. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Erasca, Inc. files it.
Also on the record for Erasca, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Jonathan E. Lim | 10.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 5.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Paradigm BioCapital Advisors LP | 3.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 6.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 5.3% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by Suvretta Capital Management, LLC | 1.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 5.7% of the class | 5%+ stakes | Source |
| January 14, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 5.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Logos Global Management LP | 4.8% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Logos Global Management LP | 5.3% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 5.3% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 7.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Erasca, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Erasca, Inc. and the records around it.
Erasca, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), ACHIEVE LIFE SCIENCES, INC. (Aug 2026), Yarrow Bioscience, Inc. (Aug 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
- Suvretta Capital Management, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Watch Erasca, Inc.
Get an email when Erasca, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Erasca, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Erasca, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Erasca, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Reported | not named in the filing | 8-K, 2026-10-16 | ||
| 2026-08-10 | In | President | 2026-08-10 | 8-K, 2026-08-10 |
Who leads Erasca, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Charles S. Fuchs, appointed, effective 2026-08-10 (filed 2026-08-10).
New leaders reset buying decisions — get the Full Report on Erasca, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at Erasca, Inc., with the record behind each one.
Find candidates like President at Erasca, Inc.Every change, in the filing's words
Reported
Accordingly, the employment of Nicholas (Nik) Chetwyn, Ph.D., the Company's Chief Operating Officer, will terminate effective November 2, 2026.
- On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs.
- Responsibilities currently overseen by the Chief Operating Officer are transitioning to other members of the Company's leadership team in order to streamline the Company's reporting structure.
Appointed: Charles S. Fuchs, President, effective 2026-08-10
Appointment of President, Research & Development Effective August 10, 2026, Charles S. Fuchs, M.D., M.P.H., was appointed President, Research & Development of Erasca, Inc. ("the Company").
- Dr. Fuchs, age 66, is a distinguished physician-scientist and internationally recognized leader in oncology with more than three decades of leadership experience in cancer research, clinical care, and biopharmaceutical drug development.
- From December 2025 to August 2026, he served as Chief Medical Officer of Tubulis GmbH (acquired by Gilead), where he oversaw clinical strategy and pipeline development.
- Prior to Tubulis, from March 2021 to December 2025 he served as Senior Vice President and Global Head of Oncology and Hematology Product Development for both Genentech and its parent company, Roche.
- Dr. Fuchs served as Director of the Yale Cancer Center and Physician-in-Chief at Smilow Cancer Hospital from January 2017 to February 2021.
- He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute from July 2007 to December 2016.
- Dr. Fuchs also serves on the board of directors of CytomX Therapeutics and as a senior advisor to Frazier Life Sciences.
- Dr. Fuchs received his medical degree from Harvard Medical School in 1986.
- He completed his medical residency at Brigham and Women's Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute.
Tools for this story
Each opens in a new tab, filled in for Erasca, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.